A 24 week phase 2b dose range finding study of RTB101 alone or in combination with RAD001 on the incidence of RTI in elderly subjects at increased risk of RTI-related morbidity and mortality.

Trial Profile

A 24 week phase 2b dose range finding study of RTB101 alone or in combination with RAD001 on the incidence of RTI in elderly subjects at increased risk of RTI-related morbidity and mortality.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 May 2017

At a glance

  • Drugs RTB101 (Primary) ; Everolimus
  • Indications Immunodeficiency disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 May 2017 According to a PureTech media release, results from this study anticipated in the second half of 2018.
    • 09 May 2017 Status changed from planning to recruiting, according to a PureTech media release.
    • 21 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top